Innoskel is a pioneering platform biotechnology company developing therapies for rare bone diseases. Innoskel's first asset is a treatment option for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which with symptoms present from birth is Spondyloepiphyseal Dysplasia congenita (SEDc), the second leading cause of dwarfism worldwide. Innoskel’s lead gene therapy asset for SEDc has demonstrated good efficacy in proof-of-concept studies. The company’s fundamental mission is to improve the lives of patients living with rare bone disorders and to answer their unmet needs, keeping their voices at the heart of all they do.